Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.34 |
| ▸ | CA12 | O43570 | 6/20 | 0.32 |
| ▸ | CA1 | P00915 | 6/20 | 0.32 |
| ▸ | CA2 | P00918 | 6/20 | 0.32 |
| ▸ | CA4 | P22748 | 6/20 | 0.32 |
| ▸ | CA7 | P43166 | 6/20 | 0.32 |
| ▸ | CA9 | Q16790 | 6/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.32 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.31 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4124600 | 0.89 | CCNE2 (0.37) | ADORA3CA1CA2CA9TMIGD3 | |
| SCHEMBL2091171 | 0.89 | ADORA2A (0.31) | ADORA2A | |
| SCHEMBL1402086 | 0.89 | ADORA2A (0.31) | ADORA2A | |
| SCHEMBL241329 | 0.87 | ADORA3 (0.36) | ADORA3CA12CA1CA2CA4 | |
| SCHEMBL1402056 | 0.87 | ADORA2A (0.38) | ADORA3ADORA2A | |
| SCHEMBL4123170 | 0.86 | ADORA2A (0.33) | ADORA3TMIGD3ADORA2ADNMT1DNMT3B | |
| Trifluoroacetic Acid SCHEMBL4119735 | 0.86 | ADORA2A (0.41) | ADORA3ADORA2ADNMT1DNMT3B | |
| SCHEMBL1402089 | 0.85 | ADORA2A (0.36) | ADORA3TMIGD3ADORA2AADORA1 | |
| SCHEMBL241436 | 0.85 | ADORA2A (0.41) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL1402138 | 0.84 | CDK1 (0.33) | ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099214-A1 | Organic Compounds | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099214-A1 | Organic Compounds | CYP3A43, OXER1, OPRM1 | ADORA3 554/4885CA12 2375/4885CA1 3545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.